Literature DB >> 17186279

Amelioration of steroids and cyclosporine-resistant nephrotic syndrome by pravastatin.

Shuichi Ito1, Hiroyuki Machida, Aya Inaba, Tomonori Harada, Kenichi Okuyama, Tomoko Nakamura, Yukoh Aihara, Shumpei Yokota.   

Abstract

We report the case of a girl with steroids and cyclosporine (CsA) resistant focal segmental glomerulosclerosis (FSGS) whose proteinuria and hypoproteinaemia were dramatically resolved by pravastatin. She had been in a nephrotic condition for 6 years. Prednisolone, pulse methylprednisolone therapy, low-density lipoprotein (LDL) apheresis, CsA, cyclophosphamide and mizoribine (MZR) had proved to be ineffective. She was started on pravastatin for her hyperlipidaemia 6 and a half years from onset, in addition to the baseline therapy, which included CsA; remission of the nephrotic syndrome was unexpectedly attained after 10 months of treatment. The baseline therapy has not been changed since the inclusion of pravastatin. This case suggests that, in patients with hyperlipidaemia, the response to CsA could be restored by lowering cholesterol levels with statins. The decrease of cholesterol levels might have improved the pharmacokinetics of CsA in this patient. Furthermore, the anti-inflammatory and immuno-modulatory effects, recently attributed to statins, may also have been involved in the improvement experienced by our patient.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17186279     DOI: 10.1007/s00467-006-0371-4

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  18 in total

Review 1.  Low density lipoprotein uptake: holoparticle and cholesteryl ester selective uptake.

Authors:  D Rhainds; L Brissette
Journal:  Int J Biochem Cell Biol       Date:  1999-09       Impact factor: 5.085

Review 2.  Lipid abnormalities in the nephrotic syndrome: the therapeutic role of statins.

Authors:  D C Wheeler
Journal:  J Nephrol       Date:  2001 Nov-Dec       Impact factor: 3.902

3.  Lipopheresis in the nephrotic syndrome.

Authors:  C Brunton; Z Varghese; J F Moorhead
Journal:  Kidney Int Suppl       Date:  1999-07       Impact factor: 10.545

Review 4.  Statins in nephrotic syndrome: a new weapon against tissue injury.

Authors:  Michele Buemi; Lorena Nostro; Eleonora Crascì; Antonio Barillà; Vincenzo Cosentini; Carmela Aloisi; Tito Sofi; Susanna Campo; Nicola Frisina
Journal:  Med Res Rev       Date:  2005-11       Impact factor: 12.944

5.  A novel anti-inflammatory role for simvastatin in inflammatory arthritis.

Authors:  Bernard P Leung; Naveed Sattar; Anne Crilly; Morag Prach; David W McCarey; Helen Payne; Rajan Madhok; Carol Campbell; J Alastair Gracie; Foo Y Liew; Iain B McInnes
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

6.  A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children.

Authors:  Motoshi Hattori; Hiroko Chikamoto; Yuko Akioka; Hyogo Nakakura; Daisuke Ogino; Akira Matsunaga; Akira Fukazawa; Sanpei Miyakawa; Miyuki Khono; Hiroshi Kawaguchi; Katsumi Ito
Journal:  Am J Kidney Dis       Date:  2003-12       Impact factor: 8.860

7.  A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma.

Authors:  Anne McKay; Bernard P Leung; Iain B McInnes; Neil C Thomson; Foo Y Liew
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

8.  Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria.

Authors:  K Kano; K Nishikura; Y Yamada; O Arisaka
Journal:  Clin Nephrol       Date:  2003-08       Impact factor: 0.975

9.  Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria.

Authors:  M E Thomas; K P Harris; C Ramaswamy; J M Hattersley; D C Wheeler; Z Varghese; J D Williams; J Walls; J F Moorhead
Journal:  Kidney Int       Date:  1993-11       Impact factor: 10.612

10.  The effect of pravastatin on acute rejection after kidney transplantation--a pilot study.

Authors:  S Katznelson; A H Wilkinson; J A Kobashigawa; X M Wang; D Chia; M Ozawa; H P Zhong; M Hirata; A H Cohen; P I Teraski
Journal:  Transplantation       Date:  1996-05-27       Impact factor: 4.939

View more
  2 in total

Review 1.  An update on LDL apheresis for nephrotic syndrome.

Authors:  Rupesh Raina; Vinod Krishnappa
Journal:  Pediatr Nephrol       Date:  2018-09-14       Impact factor: 3.714

2.  Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study.

Authors:  Eri Muso; Masatoshi Mune; Tsutomu Hirano; Motoshi Hattori; Kenjiro Kimura; Tsuyoshi Watanabe; Hitoshi Yokoyama; Hiroshi Sato; Shunya Uchida; Takashi Wada; Tetsuo Shoji; Yukio Yuzawa; Tsukasa Takemura; Satoshi Sugiyama; Yoshiki Nishizawa; Satoru Ogahara; Noriaki Yorioka; Soichi Sakai; Yosuke Ogura; Susumu Yukawa; Yasuhiko Iino; Enyu Imai; Seiichi Matsuo; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2014-06-17       Impact factor: 2.801

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.